Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Moreno et al
- PMID: 32647030
- DOI: 10.1136/annrheumdis-2020-218432
Response to: 'Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?' by Santos-Moreno et al
Keywords: antirheumatic agents; cardiovascular diseases; hydroxychloroquine.
Conflict of interest statement
Competing interests: JAS reports grants from NIH/NIAMS/NIAID/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum. AHK reports grants from NIH/NIAMS and Rheumatology Research Foundation and personal fees from Exagen Diagnostics, Inc. and GlaxoSmithKline.
Comment on
-
Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.Ann Rheum Dis. 2020 Jun;79(6):734-736. doi: 10.1136/annrheumdis-2020-217480. Epub 2020 Apr 15. Ann Rheum Dis. 2020. PMID: 32295786 Free PMC article. No abstract available.
-
Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?Ann Rheum Dis. 2022 Aug;81(8):e154. doi: 10.1136/annrheumdis-2020-218259. Epub 2020 Jul 9. Ann Rheum Dis. 2022. PMID: 32647029 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical